.23-2.33) survival. Similarly, high serum VEGF levels predicted poor overall (HR=2.35, 95 CI: 1.80-3.07) and disease-free (HR=2.36, 95 CI 1.763.16) survival. Therefore, the inhibition of angiogenesis may represent a potential therapeutic target in HCC, and many antiangiogenic agents are under evaluation in clinical trials in HCC. Bevacizumab is a recombinant humanized monoclonal antibody against VEGF which has been used either as a single agent or in combination with cytotoxic or other targeted agents in several clinical studies already concluded in Enasidenib custom synthesis Patients with advanced HCC [230-236], whereas others are still recruiting patients (Table 1). Overall, the concluded studies demonstrated that although bevacizumab is a well-tolerated agent, the side effects associated with its administration, including bleeding, hypertension, proteinuria, and thromboembolic events, warrant further evaluation. Other multiple RTK inhibitors that target VEGF are under investigation, including brivanib, linifanib (formerly ABT-869), vandetanib, and pazopanib. Recently, in a phase II trial brivanib, a selective dual inhibitor of VEGF and FGF signaling, was evaluated as a first-line therapy in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma. The study showed a median OS of 10 months. Brivanib was generally well tolerated; the most common adverse effects included fatigue, hypertension, and diarrhea [237]. Based on these results a randomized, double-blind, multi-center phase III study of brivanib versus sorafenib as first-line treatment is currently testing the OS of patients with advanced HCC who have not received prior systemicOncotarget 2012; 3: 236-therapy (NCT00858871), whereas another phase III trial, the BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib), is evaluating brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced HCC who have not responded or are intolerant to sorafenib (NCT00825955). Linifanib (ABT-869) is a novel orally active, potent and selective inhibitor of the VEGF and PDGF receptor tyrosine kinases. A phase II study on 44 patients with advanced HCC showed a purchase 6-Methoxybaicalein response rate of 7 , a median PFS of 3.7 months and median survival of 9.3 months [238]. This study concluded that linifanib is clinically active in advanced HCC, with an acceptable safety profile. On the basis of these results, a phase III study of linifanib versus sorafenib is ongoing. A phase II, placebo-controlled study of vandetanib (ZD6474), which targets VEGFR, EGFR and RET signaling, showed activity in patients with inoperable HCC but failed to meet its primary aim of tumor stabilization [239]. However, the PFS and OS results suggest that vandetanib has clinical activity in this patient population that may warrant further investigation. Finally, a report from a phase I dose-ranging study of pazopanib (GW786034), an oral inhibitor targeting VEGF, PDGF and c-kit, showed evidence of antitumor activity [240].TARGETING THE EGFR PATHWAYAnother promising target in HCC is the EGFR pathway. As mentioned above, EGFR and its ligand EGF play an important role in hepatocarcinogenesis. Two therapeutic approaches are currently being employed in clinical trials in HCC patients, by using either a monoclonal antibody neutralizing the EGFR (cetuximab) or three small-molecule tyrosine kinase inhibitors of the EGFR (erlotinib, gefinitib and lapatinb). Overall, the results have been disappointing. Indeed, in..23-2.33) survival. Similarly, high serum VEGF levels predicted poor overall (HR=2.35, 95 CI: 1.80-3.07) and disease-free (HR=2.36, 95 CI 1.763.16) survival. Therefore, the inhibition of angiogenesis may represent a potential therapeutic target in HCC, and many antiangiogenic agents are under evaluation in clinical trials in HCC. Bevacizumab is a recombinant humanized monoclonal antibody against VEGF which has been used either as a single agent or in combination with cytotoxic or other targeted agents in several clinical studies already concluded in patients with advanced HCC [230-236], whereas others are still recruiting patients (Table 1). Overall, the concluded studies demonstrated that although bevacizumab is a well-tolerated agent, the side effects associated with its administration, including bleeding, hypertension, proteinuria, and thromboembolic events, warrant further evaluation. Other multiple RTK inhibitors that target VEGF are under investigation, including brivanib, linifanib (formerly ABT-869), vandetanib, and pazopanib. Recently, in a phase II trial brivanib, a selective dual inhibitor of VEGF and FGF signaling, was evaluated as a first-line therapy in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma. The study showed a median OS of 10 months. Brivanib was generally well tolerated; the most common adverse effects included fatigue, hypertension, and diarrhea [237]. Based on these results a randomized, double-blind, multi-center phase III study of brivanib versus sorafenib as first-line treatment is currently testing the OS of patients with advanced HCC who have not received prior systemicOncotarget 2012; 3: 236-therapy (NCT00858871), whereas another phase III trial, the BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib), is evaluating brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced HCC who have not responded or are intolerant to sorafenib (NCT00825955). Linifanib (ABT-869) is a novel orally active, potent and selective inhibitor of the VEGF and PDGF receptor tyrosine kinases. A phase II study on 44 patients with advanced HCC showed a response rate of 7 , a median PFS of 3.7 months and median survival of 9.3 months [238]. This study concluded that linifanib is clinically active in advanced HCC, with an acceptable safety profile. On the basis of these results, a phase III study of linifanib versus sorafenib is ongoing. A phase II, placebo-controlled study of vandetanib (ZD6474), which targets VEGFR, EGFR and RET signaling, showed activity in patients with inoperable HCC but failed to meet its primary aim of tumor stabilization [239]. However, the PFS and OS results suggest that vandetanib has clinical activity in this patient population that may warrant further investigation. Finally, a report from a phase I dose-ranging study of pazopanib (GW786034), an oral inhibitor targeting VEGF, PDGF and c-kit, showed evidence of antitumor activity [240].TARGETING THE EGFR PATHWAYAnother promising target in HCC is the EGFR pathway. As mentioned above, EGFR and its ligand EGF play an important role in hepatocarcinogenesis. Two therapeutic approaches are currently being employed in clinical trials in HCC patients, by using either a monoclonal antibody neutralizing the EGFR (cetuximab) or three small-molecule tyrosine kinase inhibitors of the EGFR (erlotinib, gefinitib and lapatinb). Overall, the results have been disappointing. Indeed, in.